Health Condition 1: K77- Liver disorders in diseases classified elsewhere
Conditions
Interventions
Intervention1: NAC and Dexamethasone: NAC started at 12 hr prior to procedure - (150 mg per kg per hr for 1 hr followed by 12.5 mg per Kg per hr for 4 hr, then continuous infusion of 6.25 mg per kg pe
Sponsors
Institute of Liver and Biliary Sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1. All patients undergoing TACE procedure 2. Valid Consent 3. Age 18-65 years
Exclusion criteria
Exclusion criteria: 1. Child Pugh C, Child Pugh B > 8 2. HCC patients with a curative therapy (Ablation, Resection or LT) 3. ECOG Performance Status 3-4 4. Pregnancy 5. History of allergic reaction from NAC 6. significant cardiopulmonary disease 7. UGI bleed within last 28 days 8. Recent surgery within last 28 days 9. Documented febrile illness in last 1 weeks 10. Uncontrolled Diabetes (FBS > 200, HBA1C > 8) 11. Uncontrolled Hypertension (BP > 160/100) 12. Structural kidney disease with eGFR < 60 ml/min.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevention of post embolisation syndrome at 72 hours with addition of Dexamethasone to NAC in patients undergoing transarterial chemoembolisation for HCC.Timepoint: 72 hour | — |
Secondary
| Measure | Time frame |
|---|---|
| Decrease in the duration of hospitalisation with addition of Dexamethasone to NAC in patients undergoing transarterial chemoembolisation for HCC.Timepoint: 2 weeks;Prevention of post TACE decompensation at 2 weeks with addition of Dexamethasone to NAC in patients undergoing transarterial chemoembolisation for HCCTimepoint: 2 weeks;The safety of Dexamethasone & NAC in patients undergoing transarterial chemoembolisation for HCC.Timepoint: 2 weeks | — |
Countries
India
Contacts
Public ContactDr Vinod Arora
Institute of Liver and Biliary Sciences
Outcome results
None listed